>>Signaling Pathways>> Immunology/Inflammation>> 5-Lipoxygenase>>Ebselen

Ebselen

Catalog No.GC10331

글루타티온 과산화효소 모방체인 Ebselen(SPI-1005)은 강력한 전압 의존성 칼슘 채널(VDCC) 차단제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Ebselen Chemical Structure

Cas No.: 60940-34-3

Size 가격 재고 수량
50mg
US$97.00
재고 있음
100mg
US$182.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Ebselen (SPI-1005) is an inhibitor of HIV-1 capsid CTD dimerization[1]. Ebselen can permeate the blood-brain barrier and inhibit inositol monophosphatase (IMPase). Ebselen is a non-toxic seleno-organic drug with anti-inflammatory and antioxidant properties[2]. Ebselen inhibits QSOX1 enzymatic activity and has anticancer activity [3].

Ebselen (SPI-1005) inhibits early viral postentry events of the HIV-1 life cycle by impairing the incoming capsid uncoating process[1]. Ebselen permeates the blood-brain barrier and inhibits endogenous inositol monophosphatase in mouse brain[2].

References:
[1]. Thenin-Houssier S, et al. Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2195-208.
[2]. Singh N, et al. A safe lithium mimetic for bipolar disorder. Nat Commun. 2013;4:1332. doi: 10.1038/ncomms2320.
[3]. Hanavan PD, et al. Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cancer cell lines. Oncotarget. 2015 Jul 30;6(21):18418-28.

리뷰

Review for Ebselen

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ebselen

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.